SAN
FRANCISCO, March 4, 2024 /PRNewswire/ -- IDEAYA
Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology
company committed to the discovery and development of targeted
therapeutics, announced its participation in upcoming investor
relations events.
Leerink Partners Global Biopharma Conference
Monday, March 11th, 2024
at 12:40 PM ET
• Fireside chat with Yujiro S. Hata, Chief
Executive Officer, hosted by Andrew
Berens, M.D., Senior Managing Director, Targeted
Oncology
Jefferies Biotech on the Bay Summit
Tuesday, March 12th, 2024
at 8:00 AM ET
• Panel: "Novel Targeted-Oncology: Approaches,
Advancements, & Future Directions", with participation
by Yujiro S. Hata, Chief Executive Officer, hosted by
Maury Raycroft, Ph.D. Equity
Research Analyst, Biotechnology
A live audio webcast of conference events, as permitted by
conference host, will be available at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events and/or through the conference
host. A replay of available webcasts will be accessible for
30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Annual Report on Form 10-K filed on February
20, 2024 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-march-2024-investor-relations-events-302077673.html
SOURCE IDEAYA Biosciences, Inc.
